N-Acetyl Semax is a synthetic heptapeptide, an acetylated derivative of Semax, that acts through several overlapping mechanisms rather than one dominant receptor. The published record centers on rapid upregulation of neurotrophic factors, indirect modulation of several neurotransmitter systems, and melanocortin-linked anti-inflammatory signaling. Almost all of that evidence is preclinical, and neither Semax nor its acetylated form holds FDA approval in the United States.
N-Acetyl Semax is an acetylated ACTH(4-10)-derived heptapeptide whose reported brain effects arise from combined neurotrophic, neurotransmitter, and melanocortin anti-inflammatory signaling, all supported chiefly by preclinical rather than human clinical evidence.
Semax reproduces the ACTH(4-10) sequence, Met-Glu-His-Phe-Pro-Gly-Pro, the neurotropic portion of adrenocorticotropic hormone, while excluding the steroidogenic region of the hormone. That design drives central nervous system effects without prompting the adrenal cortex to release cortisol the way full-length ACTH does. N-Acetyl Semax adds an acetyl group to the N-terminus of that molecule.
Semax is built on the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro), which carries adrenocorticotropic hormone's neurotropic signaling while excluding its steroidogenic region, and N-Acetyl Semax adds an N-terminal acetyl group for added protease resistance.
The most characteristic reported action of the Semax family is upregulation of brain-derived neurotrophic factor, a protein that supports neuronal survival, new synapse formation, and memory consolidation. Rodent studies describe a single central dose raising BDNF messenger RNA and protein within hours, alongside increased expression of its high-affinity TrkB receptor, so both the signal and the cell's capacity to receive it rise together. This evidence sits at the preclinical level.
In rodent studies a single central administration of Semax has raised BDNF mRNA and protein within hours and increased expression of the TrkB receptor, with repeated dosing tending to sustain the neurotrophic effect longer than a single dose.
Rather than binding a single classical receptor, the peptide exerts a modulatory influence across several transmitter systems, which is the reported basis for effects that span attention, mood, and arousal. Much of that modulation appears indirect, operating through changes in transmitter release, turnover, and enzymatic degradation rather than through direct agonism at each receptor.
The reported neurotransmitter effects of N-Acetyl Semax are largely indirect, spanning dopaminergic, serotonergic, and cholinergic modulation plus inhibition of enkephalin-degrading enzymes, rather than direct agonism at any single receptor.
Melanocortin receptors are a family of five G-protein-coupled subtypes, MC1R through MC5R; within the central nervous system MC3R and MC4R are the most relevant, governing energy balance, inflammation control, and neuroprotection. Because Semax retains the ACTH(4-10) core, it holds a structural relationship to the natural melanocortin ligands and can engage this system without reproducing full ACTH's cortisol-releasing effect.
| Property | ACTH (full length) | N-Acetyl Semax |
|---|---|---|
| Central MC3R/MC4R engagement | Present | Present, via the ACTH(4-10) core |
| Corticotropic cortisol release | Strong | Absent, lacks the required regions |
| Anti-inflammatory neuroprotection | Present | Reported in preclinical models |
N-Acetyl Semax engages central MC3R and MC4R melanocortin receptors through its ACTH(4-10) core, activating cAMP- and protein-kinase-linked anti-inflammatory and neuroprotective signaling, while lacking the hormone regions required for ACTH's cortisol-releasing activity.
A short hydrophilic peptide does not cross the blood-brain barrier efficiently from the general circulation, so the delivery route shapes how the molecule acts in practice more than it would for a freely distributing small molecule. The common approach documented is intranasal administration, which uses the direct anatomical connection between the nasal cavity and the brain.
Because N-Acetyl Semax crosses the blood-brain barrier poorly from systemic circulation, it is typically given intranasally, using olfactory and trigeminal nerve pathways to reach central tissue within minutes to a short window after dosing.
Neuroprotection is one of the original clinical rationales for the Semax family, which was studied in the setting of ischemic stroke; Semax is a registered drug in Russia, while N-Acetyl Semax is not FDA-approved in the United States. During ischemic or hypoxic stress, neurons face a cascade of excitotoxicity, oxidative damage, and inflammation that the peptide is reported to blunt on several fronts in preclinical models.
In preclinical ischemia and hypoxia models the Semax family reduces reactive-oxygen-species accumulation, tempers microglial activation and pro-inflammatory cytokine release, and raises BDNF and NGF signaling, which together underlie its characterization as neuroprotective rather than only stimulatory.
The hypothalamic-pituitary-adrenal axis is the body's central stress-response system, in which the hypothalamus signals the pituitary to release ACTH, which drives the adrenal cortex to secrete cortisol. Because Semax derives from ACTH, a natural question is whether it hijacks this loop; the reported answer is that it does not reproduce the steroidogenic step, so its influence is regulatory and central rather than hormonal.
Although derived from ACTH, N-Acetyl Semax lacks the hormone regions required to stimulate cortisol release, so its reported effect on the stress axis is a central, mildly anxiolytic regulation rather than activation of the full adrenal cascade.
The N-acetyl modification is a small chemical change with a functional payoff: capping the free amino group at the N-terminus blocks the primary site where aminopeptidases begin degrading the peptide. Combined with the protection the Pro-Gly-Pro tail already provides at the opposite end, the two features work together to extend how long the intact molecule persists to exert its effects.
| Property | Semax | N-Acetyl Semax |
|---|---|---|
| N-terminal protection | Free amino end, exposed | Acetyl cap blocks aminopeptidase attack |
| C-terminal protection | Pro-Gly-Pro tail | Pro-Gly-Pro tail, retained |
| Duration of action | Shorter, protected at one end | Longer and steadier, protected at both ends |
N-terminal acetylation caps the peptide's free amino group, the primary aminopeptidase cleavage site, which combines with the existing Pro-Gly-Pro tail to give N-Acetyl Semax greater metabolic stability and a longer, steadier duration of action than plain Semax.
The cognitive and plasticity effects are best read as the behavioral end of a molecular chain that begins with neurotrophin upregulation and neurotransmitter modulation. Much of this evidence comes from animal and preclinical work, individual response varies, and reported cognitive benefits stand as a plausible consequence of the biology rather than a guaranteed, quantified outcome.
The reported cognitive effects of N-Acetyl Semax trace to BDNF/TrkB-driven dendritic branching and synaptic strengthening combined with dopaminergic and cholinergic modulation, an effect chain documented mainly in animal and preclinical work rather than confirmed in human clinical trials.
Educational use only. This article describes what the published scientific and clinical literature reports about N-Acetyl Semax. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
